BioXcel Therapeutics, Inc. (BTAI) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the BioXL Therapeutics second quarter 2023 financial results conference call. At this time all participants are in a listen only mode. If during the conference you require operator assistance please press star zero on your telephone keypad. After the presentation there will be a question and answer session. If you would like to register a question you may press star one on your telephone keypad. Just to remind everyone, certain matters discussed in today's conference call and or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect future results are detailed in the company's annual report on Form 10-Q for the quarter ended March 31, 2023, which can be found at www.bioexceltherapeutics.com or on www.sec.gov, and which will be updated in its quarterly report on Form 10-Q. for the quarter ended June 30th, 2023. As a reminder, today's conference is being recorded. Joining us on today's call are Dr. Vimal Mehta, Chief Executive Officer, Richard Steinhardt, Chief Financial Officer, Matt Wiley, Chief Commercial Officer, Dr. Rob Reisinger, Chief Medical Officer of Neuroscience, Dr. Vince O'Neill, Chief R&D Officer of Oncas Excel Therapeutics, and Dr. Frank Yacca, Chief Scientific Officer. It is now my pleasure to turn the call over to Dr. Amedda, the CEO and founder of BioExcel Therapeutics. Please go ahead. Thank you, operator. Welcome, everyone, and thank you for joining our call today. Before we begin, I first want to say that the company was dismayed and frustr...